LLY

765.29

-0.98%↓

JNJ

176.29

-0.52%↓

ABBV

221.49

+0.96%↑

UNH

344.26

+1.28%↑

AZN

76.43

-1.87%↓

LLY

765.29

-0.98%↓

JNJ

176.29

-0.52%↓

ABBV

221.49

+0.96%↑

UNH

344.26

+1.28%↑

AZN

76.43

-1.87%↓

LLY

765.29

-0.98%↓

JNJ

176.29

-0.52%↓

ABBV

221.49

+0.96%↑

UNH

344.26

+1.28%↑

AZN

76.43

-1.87%↓

LLY

765.29

-0.98%↓

JNJ

176.29

-0.52%↓

ABBV

221.49

+0.96%↑

UNH

344.26

+1.28%↑

AZN

76.43

-1.87%↓

LLY

765.29

-0.98%↓

JNJ

176.29

-0.52%↓

ABBV

221.49

+0.96%↑

UNH

344.26

+1.28%↑

AZN

76.43

-1.87%↓

Search

Allogene Therapeutics Inc

Open

SectorHealthcare

1.21 3.42

Overview

Share price change

24h

Current

Min

1.13

Max

1.22

Key metrics

By Trading Economics

Income

8.8M

-51M

Profit margin

272,450

Employees

226

EBITDA

-335K

-57M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+696.61% upside

Dividends

By Dow Jones

Next Earnings

6 Nov 2025

Market Stats

By TradingEconomics

Market Cap

30M

255M

Previous open

-2.21

Previous close

1.21

News Sentiment

By Acuity

50%

50%

167 / 371 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

Allogene Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

17 Sept 2025, 23:01 UTC

Acquisitions, Mergers, Takeovers

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid -- Update

17 Sept 2025, 22:48 UTC

Acquisitions, Mergers, Takeovers

Santos Confirms XRG Consortium Pulls $18.7 Billion Takeover Bid

17 Sept 2025, 21:59 UTC

Earnings

Cryptocurrency-Exchange Bullish Swings to Profit in First Report as Public Company

17 Sept 2025, 23:44 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

17 Sept 2025, 23:39 UTC

Market Talk

Gold Rises Amid Prospects of Further Fed Rate Cuts -- Market Talk

17 Sept 2025, 22:20 UTC

Acquisitions, Mergers, Takeovers

Santos: XRG Consortium Wouldn't Agree to Appropriate Risk Allocation Between It and Santos Shareholders

17 Sept 2025, 22:20 UTC

Acquisitions, Mergers, Takeovers

Santos: XRG Consortium Wouldn't Agree to Acceptable Terms That Protected Value of Transaction

17 Sept 2025, 22:20 UTC

Acquisitions, Mergers, Takeovers

Santos Had Expressed Concern to XRG Consortium About Delays in Agreeing to Scheme Implementation Agreement

17 Sept 2025, 22:19 UTC

Acquisitions, Mergers, Takeovers

Santos: Consortium Notified Board of Decision to Withdraw Proposal on Weds Evening

17 Sept 2025, 22:18 UTC

Acquisitions, Mergers, Takeovers

Santos Confirms XRG Consortium Has Withdrawn Takeover Proposal

17 Sept 2025, 21:00 UTC

Earnings

Darden Restaurants to Report Earnings. Why the Olive Garden Parent Is Expected to Stay Strong. -- Barrons.com

17 Sept 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

17 Sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 Sept 2025, 19:59 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 Sept 2025, 19:59 UTC

Market Talk

Treasury Yields, Dollar Rise as Fed Cuts, Powell Warns of Risks -- Market Talk

17 Sept 2025, 19:07 UTC

Market Talk

Oil Futures Snap Three-Session Winning Streak -- Market Talk

17 Sept 2025, 18:43 UTC

Market Talk

Treasury Yields, Dollar Reverse Course as Powell Talks to Reporters -- Market Talk

17 Sept 2025, 18:38 UTC

Market Talk

U.S. Natural Gas Futures Mixed Ahead of Storage Data -- Market Talk

17 Sept 2025, 18:20 UTC

Market Talk

Gold Dips After Quarter-Point Rate Cut -- Market Talk

17 Sept 2025, 18:18 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 Sept 2025, 18:18 UTC

Market Talk

Treasury Yields, Dollar Fall on Nearly Unanimous Fed Cut -- Market Talk

17 Sept 2025, 18:14 UTC

Market Talk

Oil Slips Some More as Fed Makes Expected 25 Bp Rate Cut -- Market Talk

17 Sept 2025, 17:59 UTC

Market Talk

Soyoil Takes Hit as Traders Consider EPA Proposal -- Market Talk

17 Sept 2025, 17:15 UTC

Acquisitions, Mergers, Takeovers

Netflix 'Has Won The Streaming Wars,' Analyst Says. The Stock Is a Buy. -- Barrons.com

17 Sept 2025, 17:06 UTC

Acquisitions, Mergers, Takeovers

Walmart Stock Heads for a Record High. The Retailer Could Become a Leader in 'Agentic' AI. -- Barrons.com

17 Sept 2025, 16:51 UTC

Earnings

Correct: Exor 1H Net Loss -EUR624M

17 Sept 2025, 16:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 Sept 2025, 16:34 UTC

Market Talk

Bank of Canada Ditches Resilience Talk, Plays Up Slowing Growth -- Market Talk

17 Sept 2025, 16:25 UTC

Earnings

Wolters Kluwer: July, August Saw a Slight Increase in Organic Growth Compared to 1H

17 Sept 2025, 16:23 UTC

Earnings

Wolters Kluwer: Year-to-Date Performance In Line With 2025 Guidance

Peer Comparison

Price change

Allogene Therapeutics Inc Forecast

Price Target

By TipRanks

696.61% upside

12 Months Forecast

Average 9.4 USD  696.61%

High 14 USD

Low 7 USD

Based on 10 Wall Street analysts offering 12 month price targets forAllogene Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

10 ratings

7

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

1.18 / 1.69Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Weak Bearish Evidence

Sentiment

By Acuity

167 / 371 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
help-icon Live chat